{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
OpGen, Inc.
Is OpGen, Inc. overvalued or undervalued?
As of August 4, 2025, OpGen, Inc. is considered undervalued with an attractive valuation grade despite significant losses and negative returns, presenting a potential investment opportunity compared to worse-performing peers.
Is OpGen, Inc. overvalued or undervalued?
As of March 30, 2016, OpGen, Inc. is rated as "risky" and overvalued, with key ratios indicating significant challenges compared to peers, despite a remarkable year-to-date return of 720.17% amidst substantial long-term losses.
Is OpGen, Inc. technically bullish or bearish?
As of June 18, 2025, OpGen, Inc. shows a mildly bullish trend overall, supported by daily moving averages, but tempered by bearish indicators in the weekly timeframe.
Who are in the management team of OpGen, Inc.?
As of March 2022, the management team of OpGen, Inc. includes Chairman William Rhodes, CEO Oliver Schacht, and Directors Mario Crovetto, Prabhavathi Fernandes, Evan Jones, and R. Donald Elsey. They oversee the company's strategic direction and operations.
What does OpGen, Inc. do?
OpGen, Inc. is a precision medicine company specializing in molecular diagnostics and informatics for infectious diseases. As of September 2024, it has a market cap of $49.13 million and reported a net profit of $9 million.
How big is OpGen, Inc.?
As of Jun 18, OpGen, Inc. has a market capitalization of 49.13 million, with net sales of 1.27 million and a net profit of -9.40 million over the last four quarters. Shareholder's funds are -11.56 million, and total assets are 1.88 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
